ODV 25 mg
Sponsors
Janssen Research & Development, LLC
Conditions
HealthyHepatic Impairment
Phase 1
A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants
CompletedNCT03155893
Start: 2017-05-12End: 2017-10-27Updated: 2017-11-14
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function
WithdrawnNCT03277755
Start: 2017-09-11End: 2017-12-22Updated: 2017-10-11